The Spark is a Lantern Pharma newsletter that provides succinct and frequent updates about Lantern, our RADR® AI and ML platform, and our pipeline of drug programs. Subscribe to the newsletter to receive it by email or see the most recent editions below.
The January 2023 edition of The Spark features the latest companyupdates including:
LP-284 was granted an FDA Orphan Drug Designation (ODD) based on its demonstrated anti-tumor activity across a comprehensive number of in vitro and in vivo models of mantle cell lymphoma (MCL).
Why it matters: The FDA grants ODDs to drugs to treat rare diseases affecting fewer than 200,000 people in the US. Receiving an ODD provides drug developers with a number of benefits including:
What’s next: Lantern is targeting filing the IND with the FDA and initiating a first-in-human Phase 1 trial for LP-284 in B-cell non Hodgkin’s lymphomas, including MCL, by mid 2023.
The big picture: Therapies for MCL rarely achieve cures and have a high percentage of relapse and resistance. There are significant needs for additional late stage options, like LP-284, for these patients.
One more thing: In addition to the ODD granted for LP-284 in MCL,Lantern was previously granted ODDs by the FDA for its drug candidateLP-184 for the treatment of malignant gliomas, atypical teratoidrhabdoid tumors (ATRT), and pancreatic cancer.
Lantern activated its fourth Harmonic™ clinical trial site in Dallas, TX at Texas Oncology. Across its four sites, Harmonic™ has 11different locations across the US, with multiple additional sites expected to be activated this quarter.
What's next: All four clinical trial sites, Gabrail Cancer Center, Northwest Oncology, New York Cancer and Blood Specialists, and Texas Oncology are in the process of screening patients and are targeting to enroll the first patients in Q1 2023.
The Harmonic™ app provides patients and caregivers with mobile access to up-to date information on the Harmonic™ trial including:
The big picture: In Q4 2022, Lantern requested a pre-investigational new drug (IND) meeting with the FDA for feedback on the company’s planned LP-184 IND application.
The positive FDA responses were in line with Lantern’s clinical, CMC and preclinical development plans and solidified a timeline for an IND submission and clinical trial initiation in Q2 2023.
What's next: The upcoming LP-184 Phase 1 trial is expected to enroll patients with solid tumors and central nervous system (CNS) cancers including:
Go deeper: Patients with central nervous system (CNS) cancers, including GBM, have some of the lowest 5 year survival rates and have had no meaningful treatment progress in two decades.
LP-184’s anti-tumor synthetic lethality mechanism of action, favorable blood brain permeability, and compelling pre-clinical efficacy for CNS cancers give it the potential to become the next generation standard-of care agent for CNS cancer patients.
This newsletter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events, our plans to advance the development of our drug candidates and antibody drug conjugate program, or our future financial performance. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the impact of the COVID-19 pandemic, (ii) the risk that our research and the research of our collaborators may not be successful, (iii) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (iv) the risk that no drug product based on our proprietary RADR® A.I. platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (v) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 10, 2022. You may access our Annual Report on Form 10-K for the year ended December 31, 2021 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this newsletter represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.